Nanograb
AI-designed multivalent nanoparticles for cell-selective drug delivery
Nanograb is a niche AI platform for nanomedicine researchers needing cell-selective delivery, but the lack of public specs and pricing makes evaluation tough. If you're early-stage and want to cut trial-and-error in particle design, it's worth a conversation. Otherwise, wait for more public evidence of its efficacy.
Verified 2d ago · liveness 42/100 · cite: rightaichoice.com/tools/nanograb
- Drug delivery researchers seeking cell-specific targeting
- Nanomedicine labs exploring AI-designed nanoparticle formulations
- Therapeutic developers aiming to reduce off-target side effects
- Early-stage teams wanting to cut trial-and-error in particle design
- Labs needing validated in vivo delivery models today
- Teams without hands-on nanoparticle formulation experience
- Researchers wanting a self-serve platform with transparent pricing
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Nanograb if you need validated in vivo delivery models today, lack hands-on nanoparticle formulation experience, or require transparent self-serve pricing and documentation.
The free tier limits you to 5 predictions per month, forcing an upgrade even for light experimentation.
Nanograb's contact-based pricing fits early-stage research teams exploring AI-driven particle design, but it lacks the transparent tiers of alternatives like Benchling, which offer per-user SaaS pricing. For serious adoption, the lack of public pricing makes budget planning difficult — you'll need a sales conversation before you can compare.
In short
Nanograb — AI-designed multivalent nanoparticles for cell-selective drug delivery. Best for Drug delivery researchers seeking cell-specific targeting, Nanomedicine labs exploring AI-designed nanoparticle formulations, Therapeutic developers aiming to reduce off-target side effects. Contact Sales pricing.
Viability Score
How well maintained and how widely used is Nanograb? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: August 2026
How we score →Key Features
- Generative AI design of multivalent nanoparticles
- Cell-selective targeting for drug delivery
- Predicts delivery parameters (size, surface chemistry, ligand density)
- Optimizes nanoparticle formulations per cell type
- Reduces off-target effects through selective targeting
- Supports gene therapy and nanomedicine research
- Predicts AAV serotype and dose
- Compare delivery efficiency across cell lines
- API access (Pro plan)
- On-premise deployment (Enterprise)
About Nanograb
Nanograb is an AI-driven platform that designs multivalent nanoparticles with cell-selective targeting for drug delivery. It helps researchers move beyond trial-and-error in particle design by using generative AI to predict and recommend delivery parameters like particle size, surface chemistry, and ligand density. The platform is built for researchers and biotechnologists in gene therapy, drug delivery, and nanomedicine who need to precisely deliver drugs to disease sites while reducing off-target effects and side effects. The platform's AI models can predict AAV serotype and dose, and compare delivery efficiency across cell lines, which shortens the path to viable formulations. It supports early-stage discovery in precision medicine, focusing narrowly on nanoparticle engineering for selective delivery rather than general lab management. That specialization is both its strength and its constraint: teams already using established transfection reagents or validated in vivo models may find the scope limited, but for those exploring AI-guided design, it offers compelling promise. Nanograb's current pricing is contact-based, with public specs sparse, which makes independent evaluation difficult. It is not a general-purpose lab informatics suite; it zeroes in on a critical need in precision medicine. For teams early in nanoparticle development, Nanograb could be worth a conversation, but buyers should weigh the lack of transparent pricing and public evidence against the potential benefits of AI-guided particle design. The focus on cell-specific targeting sets it apart from broader workflow tools like Benchling and Synthace, which do not generate particle designs.
Behind the Verdict
Nanograb targets a real problem: nanoparticle design has long been a grind of trial-and-error, and AI-guided prediction of formulation parameters could genuinely accelerate early-stage discovery. We'd reach for this when you're exploring cell-selective delivery and need to screen many design options in silico before touching the bench. The ability to predict AAV serotype and dose and compare delivery efficiency across cell lines is a practical hook for gene therapy and nanomedicine labs. Where it bites: pricing is contact-only and public specs are thin, so you can't evaluate it on your own timeline. That lack of transparency is a significant friction point, especially for academic labs with constrained budgets. If you need validated in vivo models today or are already comfortable with established transfection reagents, Nanograb may not add enough value to justify the negotiation. Compared to broader workflow platforms like Benchling or Synthace, Nanograb is not a lab management suite; it's a specialist tool for particle design. That means you'd need to integrate it alongside your existing workflow, which could be a hassle if you're not set up for it. But if you're committed to AI-driven formulation, the specialization is the point. In practice, we'd suggest reaching out for a demo and asking pointed questions about validation data and integration effort before committing. The recent news about AI training data quality is a reminder that the value of any AI tool depends on the data behind it — so it's fair to ask Nanograb what data its models are trained on. That's a reasonable diligence step for a platform that's still largely unproven in public.
Researching Nanograb? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Nanograb actually fits — and what changes day-one when you adopt it.
You're designing an AAV vector for neuronal delivery and want to predict optimal serotype and dose.
Outcome: You input your target cell type and therapeutic context, and Nanograb recommends AAV serotype and dose parameters, cutting initial screening rounds.
You need to optimize lipid nanoparticle formulations for mRNA vaccine research.
Outcome: You use Nanograb to select formulation parameters (size, surface chemistry) guided by AI, reducing the number of iterative experiments.
You're developing CAR-T therapies and need to optimize transfection of primary T cells.
Outcome: You compare delivery efficiency across cell lines in one workflow, identifying the best formulation for your T cell target.
Use Cases
- Optimize transfection of primary T cells for CAR-T therapy development
- Predict AAV serotype and dose for neuronal gene delivery
- Design electroporation parameters for CRISPR editing in iPSCs
- Select lipid nanoparticle formulation for mRNA vaccine research
- Compare delivery efficiency across multiple cell lines in a single workflow
Models Under the Hood
as of 2026-08-28
Limitations
- The free tier restricts predictions to 5 per month, which is insufficient for routine use.
- The AI model's accuracy depends on the quality and quantity of available training data for less common cell types.
- API access is only available on the Pro plan, and on-premise deployment is limited to Enterprise customers.
- Public documentation is sparse, and pricing is not transparent, requiring a sales conversation.
as of 2026-08-26
Verification history
We have re-verified Nanograb 7 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-checked, vendor evidence unchanged
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Showing the 6 most recent of 7 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where Nanograb's pricing actually pencils out — and where peers do it cheaper.
Nanograb's contact-based pricing fits early-stage research teams exploring AI-driven particle design, but it lacks the transparent tiers of alternatives like Benchling, which offer per-user SaaS pricing. For serious adoption, the lack of public pricing makes budget planning difficult — you'll need a sales conversation before you can compare.
Setup time & first value
How long it actually takes to get something useful out of Nanograb — broken out by persona, not the marketing-page minute.
For a researcher with basic nanoparticle knowledge, expect under an hour to input your cell type and therapeutic context and get initial predictions. For teams using the API or on-premise deployment, setup may take a few days depending on IT support.
Resources & Guides
Tutorials & Learning
Official links
Tools that pair well with Nanograb
Common stack mates teams adopt alongside Nanograb, with the specific reason each pairing earns its keep.
Nimbus Therapeutics
Highly selective small-molecule drug discovery for oncology, immunology, and metabolic diseases.
Recursion Pharmaceuticals
AI-native drug discovery platform turning 50+ PB of cellular imaging data into clinical-stage therapies
Recursion
AI-native drug discovery: phenomics, robotics, and a 50+ petabyte dataset to de-risk medicines.
Featured Head-to-Head Comparisons
Nanograb vs Rapidsos
RapidSOS and Nanograb serve completely different domains – emergency response vs. genetic research. Choose RapidSOS if you run a 911 center or enterprise safety program needing AI-enhanced dispatch and device data; it's deeply embedded in US public safety infrastructure with recent ESInet integration. Choose Nanograb if you're a gene therapy lab looking to reduce trial-and-error in transfection via ML-driven protocol recommendations. No overlap in use cases.
Nanograb vs Codametrix
CodaMetrix and Nanograb serve completely separate domains: CodaMetrix is an enterprise medical coding automation platform for large health systems, while Nanograb is an AI-powered gene delivery optimizer for research labs. A buyer should choose based on their industry—healthcare revenue cycle vs. biotech R&D—as there is no overlap in use cases. CodaMetrix offers proven ROI and KLAS validation; Nanograb provides a freemium entry to accelerate gene therapy experiments.
Nanograb vs Isomorphic Labs
Choose Nanograb if you need a hands-on AI tool for optimizing gene delivery in your lab with affordable freemium access. Choose Isomorphic Labs only if you are a pharma company ready for a multi-year, high-investment partnership to discover new drugs at scale — it is not a plug-and-play product.
Alternatives to Nanograb
View allNimbus Therapeutics
Highly selective small-molecule drug discovery for oncology, immunology, and metabolic diseases.
Recursion Pharmaceuticals
AI-native drug discovery platform turning 50+ PB of cellular imaging data into clinical-stage therapies
Frequently Asked Questions
Categories
Used Nanograb? Help shape our editorial sentiment research.